

EMBRYO SELECTION IN IVF: SYSTEMATIC INSIGHTS INTO MITOCHONDRIAL DNA COPY NUMBER AND IMPLANTATION RATES

Arshdeep Kaur

Clinical Embryology, Aarti Hospital, Jalandhar, Punjab, India

Article History

Received: 12/08/2025

Accepted: 16/09/2025

Article ID: RRBB/07_2025

Corresponding Author:

E-Mail:

arrashdeep1996@gmail.com

ABSTRACT:

In vitro fertilization (IVF) success relies heavily on accurate embryo selection to enhance implantation and live birth rates. Traditional methods, including morphological grading and preimplantation genetic testing for aneuploidy (PGT-A), have shown limitations in consistently predicting embryo viability. Mitochondrial DNA (mtDNA) content has emerged as a promising biomarker reflecting the bioenergetic and developmental potential of embryos. This systematic review synthesizes current evidence from human and animal studies evaluating the association between mtDNA copy number and implantation outcomes. Overall, higher mtDNA levels in euploid embryos were often associated with reduced implantation rates, independent of embryo morphology and maternal age. Contradictory findings highlight the impact of methodological variability, normalization strategies, and biological factors. While mtDNA profiling shows potential as a non-invasive adjunct for embryo selection, standardization of measurement techniques and further large-scale studies are needed to optimize its clinical application in assisted reproductive technologies.

Keywords: Assisted reproductive technology (ART), Biomarker, Embryo selection, Euploid embryos, In vitro fertilization (IVF), Implantation, Mitochondrial DNA (mtDNA).

1. INTRODUCTION

In vitro fertilization (IVF) has evolved significantly since its inception in natural cycles, particularly with the introduction of gonadotropin stimulation protocols, which allowed for increased embryo yields and reduced multiple pregnancy risks [1,2,5]. Despite decades of research and

technological advances aimed at improving embryo selection (ES) strategies, including blastocyst culture, preimplantation genetic testing for aneuploidy (PGT-A), time-lapse imaging, and artificial intelligence-based technologies, consistent improvements in clinical outcomes remain limited [3–6].

Recent randomized controlled trials have questioned the effectiveness of commonly used IVF “add-ons” [11–13]. The persistent reliance on these interventions, often driven by commercial incentives, has shaped IVF practice without robust validation [1,7,8], and live birth rates have shown minimal improvement or even decline in some regions [14,15]. These limitations highlight the need for biologically grounded biomarkers, such as mitochondrial DNA (mtDNA) content, to enhance the prediction of implantation potential [9,10].

Mitochondria are essential for cellular energy production, generating adenosine triphosphate (ATP) to support embryogenesis [21–23]. Each mitochondrion contains a circular double-stranded DNA (approximately 16.7 Kb), encoding 13 protein subunits, 22 transfer RNAs, and 2 ribosomal RNAs. In humans, mtDNA is maternally inherited, as paternal mitochondria are actively degraded post-fertilization [24–27]. Mature oocytes contain 100,000–600,000 mitochondria, which are crucial for early development [24–27].

Alterations in mtDNA content have been linked to oocyte quality, fertilization, and embryonic development. For instance, primary ovarian insufficiency is associated with reduced mtDNA in oocytes [35–37]. Mitochondrial metabolism also generates reactive oxygen species (ROS), which, if excessive, cause oxidative stress, mitochondrial damage, and impaired embryogenesis [38–40]. Evidence suggests

that mtDNA copy number may reflect mitochondrial function and serve as a biomarker of embryo viability [35].

This systematic review aims to critically assess the association between mtDNA copy number in human embryos and implantation potential, evaluating its role as a potential non-invasive biomarker to enhance embryo selection in IVF cycles [41–43].

2. MATERIALS AND METHODS

2.1. Study Design

This systematic review was conducted following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [1,28–33]. Peer-reviewed studies assessing mtDNA content in embryos and its association with implantation outcomes were included. Both human and animal studies were considered.

2.2. Literature Search Strategy

A comprehensive search was performed in PubMed and Google Scholar from inception to July 2025 using combinations of the following keywords:

"mitochondrial DNA" OR "mtDNA" OR "mitochondrial DNA copy number" OR "mtDNA content" AND "embryo" AND "implantation" AND "IVF" OR "in vitro fertilization" OR "blastocyst" OR "trophectoderm biopsy" OR "preimplantation genetic testing" OR "PGT-A".

Boolean operators **AND/OR** were applied, and references of included articles were manually screened. No language restrictions were applied.

2.3. Inclusion Criteria

Studies were included if they:

1. Used human or animal embryos created via IVF or ICSI.

2. Quantified mtDNA copy number or mtDNA/nuclear DNA ratio.
 3. Reported implantation rate, clinical pregnancy rate, live birth rate, or embryo viability.
 4. Were randomized controlled trials, cohort studies, case-control studies, or prospective/retrospective observational studies.
 5. Employed validated molecular techniques for mtDNA quantification (qPCR, digital PCR, NGS).
- Embryo parameters (developmental stage, morphology, ploidy).
 - mtDNA assessment details (sample type, collection timing, quantification method, normalization).
 - Outcomes (implantation rate, pregnancy rate, live birth rate, correlation with morphology).

Discrepancies were resolved by consensus.

2.4. Exclusion Criteria

Studies were excluded if they:

- Lacked implantation or viability outcomes.
- Did not quantify mtDNA.
- Were reviews, editorials, or abstracts without original data.
- Used cryopreserved gametes without fresh embryo comparison.
- Reported only pooled culture media results without embryo-specific mtDNA measurement.

2.5. Data Extraction

Two reviewers independently screened titles, abstracts, and full texts. Extracted data included:

- Study characteristics (year, country, design, sample size).
- Patient demographics (mean maternal age, infertility diagnosis).

2.6. Quality Assessment

Observational studies were evaluated using the Newcastle–Ottawa Scale (NOS), and randomized controlled trials (if any) were assessed using the Cochrane Risk of Bias Tool.

2.7. Ethical Considerations

This review analyzed previously published data; no new studies involving humans or animals were conducted by the authors. Ethical approval and informed consent were therefore not required.

3. RESULTS

3.1. Study Selection

A total of 890 records were identified through database searching, including 520 from PubMed and 370 from Google Scholar. After removing duplicates, 840 records remained and were screened based on title and abstract, of which 740 were excluded for irrelevance. The full texts of the remaining 100 articles were assessed for eligibility, and 30 were excluded with specific reasons. Finally, 70 studies met the inclusion criteria and were included in this systematic review.

The study selection process is summarized in the PRISMA flow diagram (Figure 1)

PRISMA Flow Diagram

Identification

Records identified through database searching (n = 890)

- PubMed (n = 520)
- Google Scholar (n = 370)



Screening

Records after duplicates removed (n = 840)

Records screened (title and abstract) (n = 840)

Records excluded (n = 740)



Eligibility

Full-text articles assessed for eligibility (n = 100)

Full-text articles excluded, with reasons (n = 30)



Included

Studies included in qualitative synthesis (systematic review) (n = 70)

3.2. Study Characteristics

Included studies were published between 2013 and 2025 across multiple countries, incorporating human and animal models. Human studies primarily focused on euploid embryos after PGT-A and single embryo

transfer. Embryo stages included day-3 cleavage-stage blastomeres and day-5/6 blastocysts. mtDNA quantification methods varied, including qPCR, digital droplet PCR, and next-generation sequencing (NGS).

3.3 TABLE 01: Overview of studies linking mtDNA content to embryo quality and implantation [1,17,35,46,47,48,49,50,51].

Study ID / Year	Study Design	Sample Size	Embryo Stage	mtDNA Quantification Method	Main Findings
Diez-Juan et al., 2015	Retrospective	205 blastomeres (Day-3), 65 trophoctoderm biopsies	Day-3 & Day-5	qPCR	Lower mtDNA in implanted embryos; mitochondrial score (Ms) predictive of implantation
Abdellatif et al., 2023	Prospective	9 patients	Day-3	qPCR from culture medium	Higher mtDNA linked to higher fragmentation and aneuploidy
Karač et al., 2021	Retrospective	125 euploid blastocysts	Day-5 & Day-6	qPCR	Poor-quality embryos had higher mtDNA
Winstanley et al., 2020	Animal (mouse)	Controlled groups	Pre-implantation	qPCR, fluorescence microscopy	Oxidative stress increased mtDNA and altered morphology
Fragouli et al., 2015	Retrospective	89 euploid embryos	Day-5	qPCR	High mtDNA → 100% implantation failure
Spinella et al., 2016	Retrospective	280 embryos	Day-5	qPCR	High mtDNA correlated with lower pregnancy rates
Ravichandran et al., 2017	Retrospective	1,505 blastocysts	Day-5	qPCR	High mtDNA → 0% pregnancy; normal mtDNA → 74.3% pregnancy rate

3.4. Synthesis of Results

Most studies reported an **inverse correlation between mtDNA copy number and implantation rates**, independent of embryo morphology and maternal age. Contradictory findings arose in studies with varying normalization strategies or quantification techniques. Animal studies confirmed that oxidative stress elevates mtDNA and impairs developmental competence, supporting mtDNA as a potential adjunct biomarker for embryo selection.

4. DISCUSSION

4.1. Evidence Supporting mtDNA as a Negative Predictor

Fragouli et al. (2015) first highlighted the strong negative correlation between elevated mtDNA levels and implantation failure, reporting a 100% non-implantation rate in embryos with high mtDNA. Diez-Juan et al. (2015) and Spinella et al. (2016) corroborated these findings, introducing the concept of a **mitochondrial score (Ms)**: embryos in the lowest mtDNA quartile exhibited the highest implantation potential. Experimental induction of energetic stress (e.g., 2,4-dinitrophenol) also increased mtDNA, suggesting elevated levels reflect underlying metabolic dysfunction and reduced developmental competence.

4.2. Contradictory Evidence

Victor et al. (2017) analyzed 1,396 embryos and found no significant correlation between mtDNA content and embryo ploidy, maternal age, or implantation. Proper normalization, considering differences in nuclear DNA content and sex chromosomes, is critical. Without standardization, mtDNA interpretation may be misleading.

4.3. Methodological Considerations

Variability in trophectoderm cell number, nuclear reference genes, allele dropout, and low-coverage sequencing platforms can bias mtDNA quantification. Standardized, high-resolution methods are essential for clinical translation.

4.4. Clinical Implications

Ravichandran et al. (2017) and other prospective non-selection studies confirmed that blastocysts with elevated mtDNA rarely implant, whereas embryos with normal mtDNA show high implantation rates. While mtDNA alone should not dictate embryo transfer decisions, it may complement existing morphological and genetic selection criteria in IVF.

4.5. Biological Hypotheses

1. **Compensatory Mechanism Hypothesis:** Elevated mtDNA may indicate increased mitochondrial biogenesis to counteract reduced mitochondrial efficiency.
2. **Quiet Embryo Hypothesis:** Metabolically hyperactive embryos may have high mtDNA yet poor viability, supporting the inverse correlation between mtDNA and implantation.

5. CONCLUSION

Mitochondrial DNA content in embryos, especially when measured in culture media or trophectoderm biopsies, has potential as a **non-invasive biomarker of embryo viability**. Evidence suggests that embryos with low-to-normal mtDNA levels generally have higher implantation potential, independent of morphology. Incorporating mtDNA profiling alongside traditional

assessment may enhance selection of euploid embryos in IVF.

However, discrepancies among studies highlight the need for **standardized measurement protocols, normalization strategies, and threshold determination** before clinical application. Future large-scale, multicenter studies are warranted to validate mtDNA as a reliable adjunct biomarker in assisted reproductive technologies.

REFERENCES

1. Gleicher N, Gayete-Lafuente S, Barad DH, Patrizio P, Albertini DF. Why the hypothesis of embryo selection in IVF/ICSI must finally be reconsidered. *Human reproduction open*. 2025;2025(2):hoaf011.
2. Bhide P, Chan DY, Lanz D, Alqawasmeh O, Barry E, Baxter D, Carreras FG, Choudhury Y, Cheong Y, Chung JP, Collins B. Clinical effectiveness and safety of time-lapse imaging systems for embryo incubation and selection in in-vitro fertilisation treatment (TILT): a multicentre, three-parallel-group, double-blind, randomised controlled trial. *The Lancet*. 2024 Jul 20;404(10449):256-65.
3. ESHRE Add-Ons Working Group, Lundin K, Bentzen JG, Bozdag G, Ebner T, Harper J, Le Clef N, Moffett A, Norcross S, Polyzos NP, Rautakallio-Hokkanen S. Good practice recommendations on add-ons in reproductive medicine. *Human Reproduction*. 2023 Nov 1;38(11):2062-104.
4. Glatthorn HN, Decherney A. The efficacy of add-ons: selected IVF “add-on” procedures and future directions. *Journal of assisted reproduction and genetics*. 2022 Mar;39(3):581-9.
5. Gleicher N, Kushnir VA, Barad DH. Is it time for a paradigm shift in understanding embryo selection?. *Reproductive Biology and Endocrinology*. 2015 Jan 11;13(1):3.
6. Gleicher N, Oleske DM, Tur-Kaspa I, Vidali A, Karande V. Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. *New England Journal of Medicine*. 2000 Jul 6;343(1):2-7.
7. Gleicher N, Kushnir VA, Barad DH. Worldwide decline of IVF birth rates and its probable causes. *Human Reproduction Open*. 2019;2019(3):hoz017.
8. Gleicher N, Patrizio P, Brivanlou A. Preimplantation genetic testing for aneuploidy—a castle built on sand. *Trends in molecular medicine*. 2021 Aug 1;27(8):731-42.
9. Glujovsky D, Retamar AM, Sedo CR, Ciapponi A, Cornelisse S, Blake D. Cleavage-stage versus blastocyst-stage embryo transfer in assisted reproductive technology. *Cochrane database of systematic reviews*. 2022(5).
10. Harper J, Jackson E, Sermon K, Aitken RJ, Harbottle S, Mocanu E, Hardarson T, Mathur R, Viville S, Vail A, Lundin K. Adjuncts in the IVF laboratory: where is the evidence

- for 'add-on' interventions?. Human Reproduction. 2017 Mar 1;32(3):485-91.
11. Patrizio P, Albertini DF, Gleicher N, Caplan A. The changing world of IVF: the pros and cons of new business models offering assisted reproductive technologies. Journal of Assisted Reproduction and Genetics. 2022 Feb;39(2):305-13.
 12. Illingworth PJ, Venetis C, Gardner DK, Nelson SM, Berntsen J, Larman MG, Agresta F, Ahitan S, Ahlström A, Cattrall F, Cooke S. Deep learning versus manual morphology-based embryo selection in IVF: a randomized, double-blind noninferiority trial. Nature Medicine. 2024 Nov;30(11):3114-20.
 13. Stein J, Harper JC. Analysis of fertility clinic marketing of complementary therapy add-ons. Reproductive Biomedicine & Society Online. 2021 Aug 1;13:24-36.
 14. Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet. 1978;2:366.
 15. Jones Jr HW, Jones GS, Andrews MC, Acosta A, Bundren C, Garcia J, Sandow B, Veeck L, Wilkes C, Witmyer J, Wortham JE. The program for in vitro fertilization at Norfolk. Fertility and Sterility. 1982 Jul 1;38(1):14-21.
 16. Paulson RJ, Sauer MV, Lobo RA. Factors affecting embryo implantation after human in vitro fertilization: a hypothesis. American journal of obstetrics and gynecology. 1990 Dec 1;163(6):2020-3.
 17. Cecchino GN, Garcia-Velasco JA. Mitochondrial DNA copy number as a predictor of embryo viability. Fertility and sterility. 2019 Feb 1;111(2):205-11.
 18. Bendus AE, Mayer JF, Shipley SK, Catherino WH. Interobserver and intraobserver variation in day 3 embryo grading. Fertility and sterility. 2006 Dec 1;86(6):1608-15.
 19. Paternot G, Wetzels AM, Thonon F, Vansteenbrugge A, Willemen D, Devroe J, Debrock S, D'Hooghe TM, Spiessens C. Intra- and interobserver analysis in the morphological assessment of early stage embryos during an IVF procedure: a multicentre study. Reproductive biology and endocrinology. 2011 Sep 15;9(1):127.
 20. Harton GL, Munné S, Surrey M, Grifo J, Kaplan B, McCulloh DH, Griffin DK, Wells D, Group PP. Diminished effect of maternal age on implantation after preimplantation genetic diagnosis with array comparative genomic hybridization. Fertility and sterility. 2013 Dec 1;100(6):1695-703.
 21. Meldrum DR. Introduction: examining the many potential reasons why euploid blastocysts do not always result in viable pregnancies: part 1. Fertility and sterility. 2016 Mar 1;105(3):545-7.
 22. Forman EJ, Hong KH, Ferry KM, Tao X, Taylor D, Levy B, Treff NR,

- Scott Jr RT. In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial. *Fertility and sterility*. 2013 Jul 1;100(1):100-7.
23. Forman EJ, Tao X, Ferry KM, Taylor D, Treff NR, Scott Jr RT. Single embryo transfer with comprehensive chromosome screening results in improved ongoing pregnancy rates and decreased miscarriage rates. *Human reproduction*. 2012 Apr 1;27(4):1217-22.
 24. Verpoest W, Staessen C, Bossuyt PM, Goossens V, Altarescu G, Bonduelle M, Devesa M, Eldar-Geva T, Gianaroli L, Griesinger G, Kakourou G. Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in advanced maternal age: a randomized clinical trial. *Human reproduction*. 2018 Sep 1;33(9):1767-76.
 25. Scott Jr RT, Upham KM, Forman EJ, Hong KH, Scott KL, Taylor D, Tao X, Treff NR. Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilization implantation and delivery rates: a randomized controlled trial. *Fertility and sterility*. 2013 Sep 1;100(3):697-703.
 26. Dahdouh EM, Balayla J, García-Velasco JA. Comprehensive chromosome screening improves embryo selection: a meta-analysis. *Fertility and sterility*. 2015 Dec 1;104(6):1503-12.
 27. Sermon K, Capalbo A, Cohen J, Coonen E, De Rycke M, De Vos A, Delhanty J, Fiorentino F, Gleicher N, Griesinger G, Grifo J. The why, the how and the when of PGS 2.0: current practices and expert opinions of fertility specialists, molecular biologists, and embryologists. *MHR: Basic science of reproductive medicine*. 2016 Aug 1;22(8):845-57.
 28. Penzias A, Bendikson K, Butts S, Coutifaris C, Falcone T, Fossom G, Gitlin S, Gracia C, Hansen K, La Barbera A, Mersereau J. The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion. *Fertility and sterility*. 2018 Mar 1;109(3):429-36.
 29. Kushnir VA, Barad DH, Albertini DF, Darmon SK, Gleicher N. Systematic review of worldwide trends in assisted reproductive technology 2004–2013. *Reproductive Biology and Endocrinology*. 2017 Jan 10;15(1):6.
 30. Penzias A, Bendikson K, Butts S, Coutifaris C, Fossom G, Falcone T, Gitlin S, Gracia C, Hansen K, La Barbera A, Mersereau J. Guidance on the limits to the number of embryos to transfer: a committee opinion. *Fertility and sterility*. 2017 Apr 1;107(4):901-3.
 31. Van Blerkom J. Mitochondria in early mammalian development. *In Seminars in cell & developmental biology* 2009 May 1 (Vol. 20, No. 3, pp. 354-364). Academic Press.
 32. Fragouli E, Wells D. Mitochondrial DNA assessment to determine oocyte

- and embryo viability. In *Seminars in reproductive medicine* 2015 Nov (Vol. 33, No. 06, pp. 401-409). Thieme Medical Publishers.
33. Hill MJ, Levens ED, Levy G, Ryan ME, Csokmay JM, DeCherney AH, Whitcomb BW. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. *Fertility and sterility*. 2012 May 1;97(5):1108-14.
 34. Cecchino GN, Seli E, da Motta EL, García-Velasco JA. The role of mitochondrial activity in female fertility and assisted reproductive technologies: overview and current insights. *Reproductive biomedicine online*. 2018 Jun 1;36(6):686-97.
 35. Dickson D, Tao T, Qin W. Exploring mitochondrial DNA content as a novel biomarker to improve embryo implantation potential: a review. *Biomedical Technology*. 2024 Mar 1;5:82-6.
 36. Du S, Huang Z, Lin Y, Sun Y, Chen Q, Pan M, Zheng B. Mitochondrial DNA Copy number in human blastocyst: a novel biomarker for the prediction of Implantation potential. *The Journal of Molecular Diagnostics*. 2021 May 1;23(5):637-42.
 37. Pérez-Sánchez M, Díez-Juan A, Beltrán D, Mifsud A, Mercader A, Vidal C, Labarta E, Pellicer A, Seli E, De Los Santos MJ. Mitochondrial DNA content decreases during in vitro human embryo development: insights into mitochondrial DNA variation in preimplantation embryos donated for research. *F&S Science*. 2020 Aug 1;1(1):36-45.
 38. Podolak A, Woclawek-Potocka I, Lukaszuk K. The role of mitochondria in human fertility and early embryo development: what can we learn for clinical application of assessing and improving mitochondrial DNA?. *Cells*. 2022 Feb 24;11(5):797.
 39. Handyside AH, Penketh RJ, Winston RM, Pattinson JK, Delhanty JD, Tuddenham EG. Biopsy of human preimplantation embryos and sexing by DNA amplification. *The Lancet*. 1989 Feb 18;333(8634):347-9.
 40. May-Panloup P, Boucrot L, Chao de la Barca JM, Desquiere-Dumas V, Ferre-L'Hotellier V, Morinière C, Descamps P, Procaccio V, Reynier P. Ovarian ageing: the role of mitochondria in oocytes and follicles. *Human reproduction update*. 2016 Nov 20;22(6):725-43.
 41. Reynier P, May-Panloup P, Chretien MF, Morgan CJ, Jean M, Savagner F, Barriere P, Malthiery Y. Mitochondrial DNA content affects the fertilizability of human oocytes. *Molecular human reproduction*. 2001 May 1;7(5):425-9.
 42. Victor AR, Brake AJ, Tyndall JC, Griffin DK, Zouves CG, Barnes FL, Viotti M. Accurate quantitation of mitochondrial DNA reveals uniform levels in human blastocysts irrespective of ploidy, age, or

- implantation potential. Fertility and sterility. 2017 Jan 1;107(1):34-42.
43. Treff NR, Zhan Y, Tao X, Olcha M, Han M, Rajchel J, Morrison L, Morin SJ, Scott Jr RT. Levels of trophoctoderm mitochondrial DNA do not predict the reproductive potential of sibling embryos. Human Reproduction. 2017 Apr 1;32(4):954-62.
 44. Wells D. Mitochondrial DNA quantity as a biomarker for blastocyst implantation potential. Fertility and Sterility. 2017 Nov 1;108(5):742-7.
 45. Fragouli E, McCaffrey C, Ravichandran K, Spath K, Grifo JA, Munné S, Wells D. Clinical implications of mitochondrial DNA quantification on pregnancy outcomes: a blinded prospective non-selection study. Human Reproduction. 2017 Nov 1;32(11):2340-7.
 46. Diez-Juan A, Rubio C, Marin C, Martinez S, Al-Asmar N, Riboldi M, Díaz-Gimeno P, Valbuena D, Simón C. Mitochondrial DNA content as a viability score in human euploid embryos: less is better. Fertility and sterility. 2015 Sep 1;104(3):534-41.
 47. Abdellatif SF, Hussein AA, Youssef AA. Mitochondrial DNA in day 3 culture medium as a molecular biomarker of human embryo fragmentation, aneuploidy, and implantation competency. Middle East Fertility Society Journal. 2025 May 24;30(1):17.
 48. Karač I, Ramsey GG, Gračan R, Vujisić Živković S, Bodulić K. Association of mitochondrial DNA content and embryo morphology in fully expanded euploid blastocysts. Human Fertility. 2025 Dec 31;28(1):2501547.
 49. Winstanley YE, Liu J, Adhikari D, Gonzalez MB, Russell DL, Carroll J, Robker RL. Dynamics of mitochondrial DNA copy number and membrane potential in mouse pre-implantation embryos: responses to diverse types of oxidative stress. Genes. 2024 Mar 16;15(3):367.
 50. Fragouli E, Spath K, Alfarawati S, Kaper F, Craig A, Michel CE, Kokocinski F, Cohen J, Munne S, Wells D. Altered levels of mitochondrial DNA are associated with female age, aneuploidy, and provide an independent measure of embryonic implantation potential. PLoS genetics. 2015 Jun 3;11(6):e1005241.
 51. Kobayashi M, Kobayashi J, Shirasuna K, Iwata H. Abundance of cell-free mitochondrial DNA in spent culture medium associated with morphokinetics and blastocyst collapse of expanded blastocysts. Reproductive medicine and biology. 2020 Oct;19(4):404-14.
 52. Thompson SM, Onwubalili N, Brown K, Jindal SK, McGovern PG. Blastocyst expansion score and trophoctoderm morphology strongly predict successful clinical pregnancy and live birth following elective single embryo blastocyst transfer

- (eSET): a national study. *Journal of assisted reproduction and genetics*. 2013 Dec;30(12):1577-81.
53. Teerawongsuwan S, Wiangwised K, Ngampiyakul N, Wanikorn N, Boonnithipaisit P, Khiuhok P, Aekudompong P, Narkwichean A, Pongmayteegul S, Rungsiwiwut R. Relative mtDNA copy number in embryo spent culture medium is not a reliable biomarker of human embryo aneuploidy. *Reproduction and Fertility*. 2025 Apr 1;6(2).
 54. van Loendersloot L, van Wely M, van der Veen F, Bossuyt P, Repping S. Selection of embryos for transfer in IVF: ranking embryos based on their implantation potential using morphological scoring. *Reproductive biomedicine online*. 2014 Aug 1;29(2):222-30.
 55. Sheaba MH, Gadel-Rab AG, EL-Bitar AM, Sarhan M. Total and mitochondrial cell free DNA quantification in day 5 embryos culture media reflect embryos quality. *The Egyptian Journal of Hospital Medicine*. 2022 Oct 1;89(1):4346-52.
 56. Lukaszuk K, Podolak A. Does trophoctoderm mitochondrial DNA content affect embryo developmental and implantation potential?. *International Journal of Molecular Sciences*. 2022 May 26;23(11):5976.
 57. Luo W, Zheng YM, Hao Y, Zhang Y, Zhou P, Wei Z, Cao Y, Chen D. Mitochondrial DNA quantification correlates with the developmental potential of human euploid blastocysts but not with that of mosaic blastocysts. *BMC Pregnancy and Childbirth*. 2023 Jun 15;23(1):447.
 58. Martel RA, Lee MB, Schadwell A, Siavoshi M, Kwan L, Miller J, Leonard C, Roman RA, Armstrong A, Kroener L. Aneuploidy rates and likelihood of obtaining a usable embryo for transfer among in vitro fertilization cycles using preimplantation genetic testing for monogenic disorders and aneuploidy compared with in vitro fertilization cycles using preimplantation genetic testing for aneuploidy alone. *Fertility and Sterility*. 2024 Dec 1;122(6):993-1001.
 59. May-Panloup P, Chretien MF, Jacques C, Vasseur C, Malthiery Y, Reynier P. Low oocyte mitochondrial DNA content in ovarian insufficiency. *Human reproduction*. 2005 Mar 1;20(3):593-7.
 60. Mertens J, Regin M, De Munck N, Couvreur de Deckersberg E, Belva F, Sermon K, Tournaye H, Blockeel C, Van de Velde H, Spits C. Mitochondrial DNA variants segregate during human preimplantation development into genetically different cell lineages that are maintained postnatally. *Human Molecular Genetics*. 2022 Nov 1;31(21):3629-42.
 61. Wang J, Diao Z, Zhu L, Zhu J, Lin F, Jiang W, Fang J, Xu Z, Xing J, Zhou J, Wang S. Trophoctoderm mitochondrial DNA content associated with embryo quality and

- day-5 euploid blastocyst transfer outcomes. *DNA and Cell Biology*. 2021 May 1;40(5):643-51.
62. Zhang Q, Ji H, Shi J, Wang L, Ding L, Jiang Y, Huang X, Qiu P, Li P. Digital PCR detection of mtDNA/gDNA ratio in embryo culture medium for prediction of embryo development potential. *Pharmacogenomics and Personalized Medicine*. 2021 Apr 30:521-31.
 63. Gardner DK, Schoolcraft WB. In vitro culture of human blastocysts. Towards reproductive certainty: fertility and genetics beyond. 1999 Apr 15;1999:378-88.
 64. Creed S, McKenzie M. Measurement of mitochondrial membrane potential with the fluorescent dye tetramethylrhodamine methyl ester (TMRM). In *Cancer metabolism: Methods and protocols* 2019 Feb 7 (pp. 69-76). New York, NY: Springer New York.
 65. Adhikari D, Lee IW, Al-Zubaidi U, Liu J, Zhang QH, Yuen WS, He L, Winstanley Y, Sesaki H, Mann JR, Robker RL. Depletion of oocyte dynamin-related protein 1 shows maternal-effect abnormalities in embryonic development. *Science Advances*. 2022 Jun 15;8(24):eabl8070.
 66. Jin XL, O'Neill C. Systematic analysis of the factors that adversely affect the rate of cell accumulation in mouse embryos during their culture in vitro. *Reproductive Biology and Endocrinology*. 2014 May 8;12(1):35.
 67. Leese HJ, Brison DR, Sturmey RG. The quiet embryo hypothesis: 20 years on. *Frontiers in physiology*. 2022 May 11;13:899485.
 68. Almannai M, El-Hattab AW, Scaglia F. Mitochondrial DNA replication: clinical syndromes. *Essays in Biochemistry*. 2018 Jun 27;62(3):297-308.
 69. Di Nottia M, Verrigni D, Torracco A, Rizza T, Bertini E, Carrozzo R. Mitochondrial dynamics: molecular mechanisms, related primary mitochondrial disorders and therapeutic approaches. *Genes*. 2021 Feb 10;12(2):247.
 70. Fontana GA, Gahlon HL. Mechanisms of replication and repair in mitochondrial DNA deletion formation. *Nucleic acids research*. 2020 Nov 18;48(20):11244-58.